JNJ logo

Johnson & Johnson Stock Price

NYSE:JNJ Community·US$460.2b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 810 Fair Values set on narratives written by author

JNJ Share Price Performance

US$190.72
30.21 (18.82%)
3.0% overvalued intrinsic discount
US$185.13
Fair Value
US$190.72
30.21 (18.82%)
3.0% overvalued intrinsic discount
US$185.13
Fair Value
Price US$190.72
AnalystConsensusTarget US$185.13
Goran_Damchevski US$173.55
StjepanK US$133.00

JNJ Community Narratives

AnalystConsensusTarget·
Fair Value US$185.13 2.5% overvalued intrinsic discount

US 55 Billion Investment Will Drive Breakthrough Therapies

6users have liked this narrative
0users have commented on this narrative
407users have followed this narrative
Goran_Damchevski·
Fair Value US$173.55 9.3% overvalued intrinsic discount

Rich Drug Pipeline Will Push Revenues and Earnings Higher

17users have liked this narrative
1users have commented on this narrative
28users have followed this narrative
StjepanK·
Fair Value US$133 42.6% overvalued intrinsic discount

Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth

15users have liked this narrative
0users have commented on this narrative
13users have followed this narrative

Recent JNJ News & Updates

Johnson & Johnson Key Details

US$90.6b

Revenue

US$28.6b

Cost of Revenue

US$62.0b

Gross Profit

US$39.3b

Other Expenses

US$22.7b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
Oct 14, 2025
Earnings per share (EPS)
9.41
Gross Margin
68.41%
Net Profit Margin
25.00%
Debt/Equity Ratio
64.7%

Johnson & Johnson Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Outstanding track record established dividend payer.

3 Risks
3 Rewards

About JNJ

Founded
1886
Employees
138100
CEO
Joaquin Duato
WebsiteView website
www.jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
The market has stayed flat over the 7 days. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›